Executive Summary
The IPO pipeline is surging with 12 new filings on July 2, 2026, dominated by SPACs (4 of 13) and traditional IPOs (Jersey Mike's, Scribe Therapeutics, Dear Industrial Gas, Cycurion).
The most notable trend is the extreme financial fragility among several IPO candidates: Scribe Therapeutics shows a 5x widening in net losses and negative working capital, while Dear Industrial Gas has zero revenue and no governance structure. Period-over-period data reveals a stark contrast between established operators like Jersey Mike's (50% cumulative same-store sales growth 2020-2025) and pre-revenue biotechs. The M&A pipeline is equally active with three major S-4 filings: Sysco's $1.164B termination-fee-laden acquisition of Jetro Restaurant Depot, Olin-Huntsman's merger of equals, and Gentherm's Reverse Morris Trust acquisition of Modine's Performance Technologies. Insider activity is notably absent across all filings, but capital allocation signals are mixed—Jersey Mike's proceeds will repay debt while SPACs offer no near-term returns. The most critical development is the concentration of SPAC filings (B&R Technology, Laris Growth, Gold Mountain) targeting $600M+ in aggregate proceeds, signaling renewed blank-check appetite despite regulatory headwinds.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: S-1
Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from June 24, 2026.
Investment Signals (12)
- Jersey Mike's Subs ↓ (BULLISH)▲
50% cumulative same-store sales growth (2020-2025), $4.3B systemwide sales, 3,300 locations, 12M+ active loyalty customers—strongest operational metrics in the IPO pipeline
- Scribe Therapeutics ↓ (BEARISH)▲
Collaboration revenue collapsed 87% YoY ($17.1M to $2.2M), net loss widened 409% ($3.4M to $17.3M), negative working capital of $(27.3M)—severe financial deterioration ahead of IPO
- Dear Industrial Gas ↓ (BEARISH)▲
Zero revenue, zero compensation for all 6 directors/officers, no audit committee, no code of ethics—extreme governance red flags for a public offering
- Cycurion ↓ (BEARISH)▲
Revenue grew strongly in FY2025 but Q1 2026 revenue declined vs Q1 2025, complex capital structure with 8 series of convertible preferred stock—dilution risk for IPO investors
- Peraso Inc ↓ (BEARISH)▲
$25M equity line facility at fluctuating market price ($0.83 assumed), 31.75M shares registered for resale, Exchange Cap of 3M shares requiring stockholder approval—massive dilution risk
- Sysco/Jetro Restaurant Depot (MIXED)▲
Termination fee of $1.164B (16% of equity value), HSR clearance pending, 84%/16% ownership split—high-stakes deal with significant regulatory risk
- Olin-Huntsman Merger ↓ (MIXED)▲
0.5476 exchange ratio, potential refinancing of $500M+ in Huntsman notes at higher rates, both boards unanimously recommend—synergy potential but debt overhang
- Gentherm/Modine PT ↓ (NEUTRAL)▲
$210M cash distribution to Modine, $45M termination fee, Reverse Morris Trust structure with tax advantages—complex but potentially value-accretive
- Gold Mountain Acquisition Corp ↓ (NEUTRAL)▲
$75M SPAC targeting Asia (ex-China VIE), 24-month completion window, EarlyBirdCapital firm commitment underwriting—niche focus but PRC regulatory risks
- Laris Growth Acquisition Corp ↓ (BEARISH)▲
Sponsor paid $0.003/share for 7.67M founder shares ($25K total) vs $10/unit public offering—immediate 3,333x dilution for public shareholders
- B&R Technology Merger Corp ↓ (NEUTRAL)▲
$325M SPAC, 24-27 month completion window, sponsor private placement of 687,500 units at $10—largest SPAC in this batch but no target identified
- ▲
NIMU parent equity improved 64.9% YoY to $244K but declined 27.8% from Dec 2025, Gravitics net loss doubled to $4.5M in Q1 2026—micro-cap combination with deteriorating trends
Risk Flags (10)
- Scribe Therapeutics/Financial Deterioration↓ [HIGH RISK]▼
Revenue collapsed 87% YoY, net loss widened 409%, negative working capital of $(27.3M), total liabilities ($103.6M) exceed total assets ($65.2M)—IPO may be last resort financing
- Dear Industrial Gas/Governance Failure↓ [HIGH RISK]▼
No audit committee, no independent directors, no code of ethics, no compensation for executives—fails basic SEC/FINRA listing standards
- Peraso Inc/Dilution Risk↓ [HIGH RISK]▼
$25M equity line at market price, 31.75M shares registered, Exchange Cap triggers Nasdaq stockholder approval—existing holders face severe dilution
- Laris Growth Acquisition Corp/Sponsor Dilution↓ [HIGH RISK]▼
Founder shares at $0.003 vs $10 public offering price—3,333x cost advantage creates misaligned incentives
- Gold Mountain Acquisition Corp/PRC Regulatory Risk↓ [MEDIUM RISK]▼
Focus on Asia/China targets, HFCA Act exposure, no VIE structures allowed—regulatory uncertainty could prevent any deal
- Sysco/Jetro Restaurant Depot Termination Fee [MEDIUM RISK]▼
$1.164B termination fee (16% of deal value) creates asymmetric risk—regulatory denial could cost Sysco billions
- Olin-Huntsman/Refinancing Risk↓ [MEDIUM RISK]▼
If subsidiary merger structure used, 2.950% and 4.500% Huntsman notes must be refinanced at current higher rates—materially reduces net income
- Non-Invasive Monitoring Systems/Equity Erosion↓ [HIGH RISK]▼
Parent equity declined 27.8% from Dec 2025 to $244K, Gravitics burning $4.5M/quarter—combined entity may run out of cash within months
- Cycurion/Complex Capital Structure↓ [MEDIUM RISK]▼
8 series of convertible preferred stock plus multiple warrant series—valuation and dilution impossible to model for IPO investors
- InMed Pharmaceuticals/No Deal Details↓ [MEDIUM RISK]▼
S-4 filed with zero quantitative data, no parties identified, no strategic rationale—could be a reverse merger with adverse terms
Opportunities (9)
- Jersey Mike's Subs/IPO↓ (OPPORTUNITY)◆
50% same-store sales growth, $1.4M AUV, 12M+ loyalty members, Blackstone backing—best-in-class QSR operator entering public markets
- B&R Technology Merger Corp/SPAC↓ (OPPORTUNITY)◆
$325M trust, 24-month window, sponsor skin-in-the-game with 687,500 private units—largest SPAC in batch with management incentives aligned
- Gentherm/Modine PT Merger↓ (OPPORTUNITY)◆
Reverse Morris Trust structure offers tax efficiency, $227.2M target net working capital with upside adjustment—potential for value creation through synergies
- Gold Mountain Acquisition Corp/Asia Focus↓ (OPPORTUNITY)◆
$75M SPAC targeting Asia ex-VIE, differentiated from crowded US-focused SPACs—could attract premium targets
- Olin-Huntsman Merger of Equals↓ (OPPORTUNITY)◆
Both boards unanimously recommend, potential cost synergies from combined chemicals platform—if refinancing risks managed, could create value
- Cycurion/Revenue Growth↓ (OPPORTUNITY)◆
Strong FY2025 revenue growth, SLG Innovation acquisition adds capabilities—if Q1 2026 revenue decline is seasonal, IPO could re-rate
- Laris Growth Acquisition Corp/Deep-Tech Focus↓ (OPPORTUNITY)◆
Targeting high-growth deep-tech businesses, $200M trust—niche focus could attract quality targets in AI/hardware
- Non-Invasive Monitoring Systems/Gravitics Combo↓ (OPPORTUNITY)◆
Space technology (Gravitics) via micro-cap shell, Series A Preferred increased 117% to $5.0M—insider confidence in space thesis
- Scribe Therapeutics/Pipeline Value↓ (OPPORTUNITY)◆
Lead candidate STX-1150 and pipeline (STX-1200, STX-1400) targeting large markets—if IPO proceeds fund development, asymmetric upside
Sector Themes (6)
- SPAC Renaissance◆
4 of 13 filings are SPACs (B&R Technology $325M, Laris Growth $200M, Gold Mountain $75M, plus B&R's $6.9M sponsor placement)—aggregate $600M+ in SPAC IPO proceeds signals renewed blank-check appetite after 2023-2025 lull
- Financial Fragility in Biotech IPOs◆
Scribe Therapeutics (negative working capital, 409% loss widening) and Dear Industrial Gas (zero revenue, no governance) highlight deteriorating quality of IPO candidates—investors must scrutinize cash runways
- QSR Strength vs Tech Weakness◆
Jersey Mike's (50% same-store sales growth) contrasts sharply with Scribe Therapeutics (87% revenue decline)—consumer staples IPOs showing resilience while pre-revenue tech struggles
- M&A Structural Innovation◆
Three S-4 filings use complex structures—Sysco/JRD (merger with termination fee), Olin/Huntsman (merger of equals with refinancing risk), Gentherm/Modine (Reverse Morris Trust)—shows dealmakers using creative structures to close valuation gaps
- Governance Arbitrage◆
Dear Industrial Gas (no audit committee, no independent directors) vs Jersey Mike's (controlled company by Blackstone)—wide dispersion in IPO governance quality creates opportunities for activist investors post-listing
- Dilution as Financing Tool◆
Peraso ($25M equity line at market) and Laris Growth (sponsor shares at $0.003) show companies using aggressive dilution mechanisms—sign of desperation or opportunity depending on execution
Watch List (8)
- Sysco/Jetro Restaurant Depot👁
HSR Act clearance decision—regulatory approval or denial could trigger $1.164B termination fee, watch for DOJ/FTC challenges
- Jersey Mike's Subs IPO Pricing👁
No price range disclosed yet—watch for S-1 amendment with proposed range and number of shares, expected within 30-60 days
- Scribe Therapeutics Cash Runway👁
With $17.3M quarterly burn and negative working capital, watch for additional financing needs or down-round risk before IPO closes
-
Special meetings scheduled for 2026—watch for institutional shareholder support or opposition, especially on compensation proposals
-
24-month window starting—watch for any business combination announcements in Asia ex-VIE, particularly in technology or manufacturing
-
If Exchange Cap (3,004,114 shares) exceeded, Nasdaq requires stockholder vote—watch for proxy filing and dilution limits
-
$210M cash distribution and $45M termination fee—watch for regulatory approvals and SpinCo financing completion
- Dear Industrial Gas SEC Review👁
With zero governance structure, watch for SEC comment letters or withdrawal—filing may not go effective without significant amendments
Filing Analyses
(13)
02-07-2026
Sysco is acquiring Jetro Restaurant Depot (JRD) and Warehouse Realty via a merger, with JRD and Warehouse Realty equityholders expected to hold approximately 16% and Sysco stockholders approximately 84% of the combined entity, Sysco Holdings. The transaction is subject to HSR Act clearance and other customary conditions, and Sysco could owe a termination fee of $1.164 billion under certain circumstances. Risks include potential failure to realize anticipated synergies, regulatory delays or conditions, and litigation, while existing Sysco stockholders will have a reduced ownership stake in the combined company.
- · The transaction is subject to HSR Act waiting period expiration or termination and other customary conditions.
- · Sysco could owe a termination fee of $1.164 billion under certain circumstances.
- · Post-closing, JRD and Warehouse Realty equityholders are expected to hold approximately 16% and Sysco stockholders approximately 84% of Sysco Holdings common stock.
- · Sysco stockholders will have reduced ownership and economic interest in Sysco Holdings compared to their current ownership of Sysco.
- · Jetro Restaurant Depot is privately held with limited publicly available information; its financial statements have not been subject to SEC review.
- · Completion of the transaction may trigger change-in-control provisions in certain Jetro Restaurant Depot agreements.
- · Sysco equityholders do not have appraisal rights in connection with the transaction.
- · Potential litigation could result in substantial costs, an injunction preventing completion, or damages.
- · Regulatory authorities may impose conditions that could delay, prevent, or increase costs of the transaction.
02-07-2026
Dear Industrial Gas Inc filed an S-1 registration statement for an IPO on July 2, 2026. The company has no revenue, no owned or rented properties, no patents or trademarks, and no formal code of ethics, audit committee, or independent directors. All six directors and executive officers received zero compensation in fiscal 2026, and the company has not granted any stock options.
- · The company has no formal audit committee, compensation committee, or nominating committee.
- · No director qualifies as an 'audit committee financial expert' or as an independent director under SEC/FINRA rules.
- · The company has not adopted a formal code of ethics.
- · All six directors and executive officers received $0 total compensation in fiscal year 2026.
- · The company has not granted any stock options since incorporation.
- · The company does not own or rent any properties; it uses office space at 10368 LOZANO CUPERTINO, California 95014-6607 at no charge.
- · No legal proceedings are pending against the company or its officers/directors.
- · The company has no patents or trademarks, nor has it applied for any.
02-07-2026
Jersey Mike's Subs Inc. filed an S-1 registration statement on July 2, 2026, for an initial public offering of Class A common stock to be listed on the NYSE under the symbol 'JMKE'. The company highlights 3,300 locations, $4.3 billion in systemwide sales, and $1.4 million AUV, with 50% cumulative same-store sales growth from 2020-2025 and over 12 million active loyalty customers. However, the filing does not disclose the proposed price range or number of shares, and the company will be a 'controlled company' by Blackstone affiliates post-offering, which introduces governance risks.
- · The company will have a dual-class structure with Class A and Class B common stock, each with one vote per share.
- · Blackstone affiliates will hold a majority of voting power post-offering, making Jersey Mike's a 'controlled company' under NYSE rules.
- · Proceeds from the offering will be used to acquire Common Units from Jersey Mike's HoldCo, LLC, which will repay indebtedness and for general corporate purposes.
- · The underwriters have a 30-day option to purchase up to an additional shares from selling stockholders.
- · The company has applied to list on the NYSE under the symbol 'JMKE'.
- · The filing does not include the proposed price range or number of shares to be offered.
02-07-2026
Non-Invasive Monitoring Systems Inc. (NIMU) filed an S-4 registration statement on July 2, 2026, in connection with a business combination with Gravitics Inc. The filing includes financial statements for Gravitics, which incurred a net loss of $4.5 million in Q1 2026 compared to a $2.0 million loss in Q1 2025. Meanwhile, NIMU's parent company shows total stockholders' equity of $244,000 as of March 31, 2026, down from $338,000 at year-end 2025, driven by ongoing losses and related-party promissory notes from Dr. Jane Hsiao and Frost Gamma Investments Trust.
- · Gravitics Inc. had total assets as of March 31, 2026, of $250,000 in equity, down from $4.5M at year-end 2025, implying significant net losses in Q1 2026.
- · Gravitics' Series Seed Preferred Stock remained at $6.5M across all periods (Dec 2024, Dec 2025, Mar 2026), while Series A Preferred increased from $2.3M to $5.0M between Dec 2025 and Mar 2026.
- · Non-Invasive Monitoring Systems parent company total stockholders' equity improved from $148,000 (Mar 31, 2025) to $244,000 (Mar 31, 2026), a 64.9% increase year-over-year, but declined 27.8% from $338,000 (Dec 31, 2025).
- · Related-party notes payable increased in Q1 2026 with new promissory notes issued on January 5, 2026, to Dr. Jane Hsiao and Frost Gamma Investments Trust.
02-07-2026
Olin Corporation and Huntsman Corporation have entered into a merger agreement for a merger of equals business combination. Under the terms, Huntsman stockholders will receive 0.5476 shares of Olin common stock for each share of Huntsman common stock held. The transaction is structured as either a direct merger (preferred) or a subsidiary merger; if the subsidiary merger is used, certain Huntsman notes (2.950% Senior Notes due 2031 and 4.500% Senior Notes due 2029) will likely need to be refinanced at higher interest rates, reducing net income. Both boards unanimously recommend approval, and special meetings of shareholders are scheduled for 2026.
- · Olin common stock trades on NYSE under symbol 'OLN'; Huntsman common stock trades under 'HUN'.
- · Olin shareholders will vote on four proposals: Olin direct merger proposal, Olin subsidiary merger proposal, Olin advisory compensation proposal, and Olin adjournment proposal.
- · Huntsman stockholders will vote on three proposals: Huntsman merger proposal, Huntsman advisory compensation proposal, and Huntsman adjournment proposal.
- · If the subsidiary merger is used, refinancing of the 2.950% Senior Notes due 2031 and 4.500% Senior Notes due 2029 will likely be required, with new debt at higher interest rates, reducing net income.
- · The merger is subject to customary closing conditions, including approval by both sets of shareholders.
02-07-2026
InMed Pharmaceuticals Inc. filed a Business Combination on July 2, 2026, but the filing does not disclose specific deal structure, parties, valuation, or strategic rationale. No quantitative data or scheduled events are provided. The analysis is limited due to lack of information.
02-07-2026
Scribe Therapeutics, Inc. filed an S-1 registration statement on July 2, 2026, for an initial public offering of common stock to be listed on Nasdaq under the symbol 'SCTX'. The company plans to use net proceeds to advance its lead product candidate STX-1150 and other pipeline programs (STX-1200, STX-1400) and for working capital. However, the filing reveals a deteriorating financial position: collaboration revenue collapsed from $17.1M in Q1 2025 to $2.2M in Q1 2026, while net loss widened from $3.4M to $17.3M over the same period, and the company had negative working capital of $(27.3M) as of March 31, 2026.
- · The company had negative working capital of $(27.3M) as of March 31, 2026.
- · Total liabilities ($103.6M) exceeded total assets ($65.2M) as of March 31, 2026.
- · Stockholders' deficit was $(158.7M) as of March 31, 2026.
- · The convertible note balance was $40.5M as of March 31, 2026, with a $4.6M change in fair value loss in Q1 2026.
- · Weighted-average shares outstanding for Q1 2026 were 14,572,357.
- · The company has applied to list on Nasdaq under the symbol 'SCTX'.
- · The offering includes a 30-day underwriters' option to purchase additional shares.
- · The company will adopt a 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan effective prior to the IPO.
02-07-2026
B&R Technology Merger Corp. filed an S-1 registration statement on July 2, 2026, for an initial public offering of 32,500,000 units at $10.00 per unit, targeting $325,000,000 in gross proceeds. The SPAC has not yet selected a business combination target and has a 24-month completion window (extendable to 27 months under certain conditions). The filing includes a sponsor private placement of 687,500 units (up to 760,625 if over-allotments are exercised) at $10.00 per unit for a total of $6,875,000 (up to $7,606,250).
- · The warrants become exercisable 30 days after the completion of the initial business combination and expire five years after such combination (or earlier upon redemption or liquidation).
- · The private placement warrants are not redeemable by the company.
- · Public shareholders can redeem their Class A ordinary shares at a per-share price equal to the trust account balance (including interest, less permitted withdrawals) divided by the number of outstanding public shares, upon completion of the initial business combination.
- · If no business combination is completed within the completion window, the company will redeem 100% of the public shares from the trust account (less up to $100,000 of interest income for dissolution expenses).
- · Shareholders holding more than 15% of the shares sold in the offering may be restricted from redeeming their shares without prior consent if a shareholder vote is sought.
- · The company may extend the completion period from 24 months to 27 months if a letter of intent, agreement in principle, or definitive agreement is executed within the initial 24 months.
02-07-2026
Peraso Inc. filed an S-1 registration statement on July 2, 2026, to register up to 31,750,000 shares of common stock for resale by Roth Principal Investments, pursuant to a Purchase Agreement entered on June 30, 2026, under which Roth Principal Investments committed to purchase up to $25,000,000 of shares over 36 months. The offering poses significant dilution risk to existing stockholders, as the purchase price will fluctuate based on market price (assumed at $0.83 per share), and the company may require additional financing to sustain operations, with no guarantee of sufficient funding.
- · The Purchase Agreement was entered on June 30, 2026, and the commitment period is 36 months following the effective date of the registration statement.
- · The company is authorized to issue 20,000,000 shares of preferred stock, which could further dilute common stockholders.
- · If the Exchange Cap (3,004,114 shares) is exceeded, stockholder approval is required under Nasdaq rules.
- · The company may still need additional capital even if it sells the full $25,000,000 commitment.
- · Roth Principal Investments may resell shares at any time and at different prices, leading to varying dilution for different investors.
02-07-2026
Laris Growth Acquisition Corp. filed an S-1 registration statement for an initial public offering of 20,000,000 units at $10.00 per unit, targeting up to $200,000,000 in gross proceeds. The blank check company will focus on acquiring a high-growth deep-tech business. However, the sponsor acquired 7,666,667 founder shares for only $25,000 ($0.003 per share), creating immediate and substantial dilution for public shareholders, and no business combination target has been selected or discussions initiated.
- · Warrants: Each whole warrant entitles holder to purchase one Class A ordinary share at $11.50 per share, exercisable 30 days after initial business combination, expiring 5 years after.
- · Redemption limitation: Any public shareholder with more than 15% of shares sold in the offering is restricted from redeeming those excess shares without company consent (if shareholder vote is used).
- · Non-managing sponsor investors (up to 325,000–355,000 private units) have expressed interest but commitments are non-binding; they may purchase fewer or none.
- · The underwriter receives full upfront discounts and deferred underwriting commissions on units purchased by non-managing sponsor investors.
- · No business combination target has been selected nor any substantive discussions initiated.
- · Immediate dilution: sponsor purchased founder shares at $0.003 per share versus public offering price of $10.00 per unit.
02-07-2026
Gold Mountain Acquisition Corp. filed an S-1 registration statement for an initial public offering of 7,500,000 units at $10.00 per unit, with total gross proceeds of $75.0 million. The SPAC intends to focus on target businesses in Asia, particularly China, but will not consummate a business combination with an entity using a VIE structure. The filing highlights significant risks related to PRC regulatory uncertainties, potential limitations on foreign ownership, and the Holding Foreign Companies Accountable Act, which could materially affect the value of the securities or the company's ability to complete a business combination.
- · The ordinary shares, rights, and warrants will trade on Nasdaq under symbols GDMT, GDMTR, and GDMTW respectively after the units begin separate trading.
- · The underwriter (EarlyBirdCapital, Inc.) is offering the units on a firm commitment basis.
- · The company will not consummate a business combination with an entity using a VIE structure in China.
- · The auditor, Golden Eagle CPAs LLC, is headquartered in Bedminster, New Jersey, and is not subject to the PCAOB's December 2021 determination under the HFCAA.
- · Certain sponsors' limited partners and certain officers/directors are located in or have significant ties to China, which may limit the pool of acquisition candidates outside the PRC.
02-07-2026
Cycurion, Inc. filed an S-1 registration statement for its IPO on July 2, 2026, providing financial results for the periods ended March 31, 2026, and December 31, 2025 and 2024. The filing details the company's complex capital structure with multiple series of convertible preferred stock and warrants, and includes the acquisition of SLG Innovation Inc. Revenue grew strongly in 2025, but the company reported a net loss for the year, and the first quarter of 2026 showed a decline in revenue compared to the same period in 2025.
- · The filing includes financial data for the three months ended March 31, 2026 and 2025, and for the years ended December 31, 2025 and 2024.
- · The company has multiple series of convertible preferred stock: Series A, A-1, B, C, D, E, F, and G.
- · Warrants include Series A, B, D, and Common Stock warrants.
- · The company acquired SLG Innovation Inc. and is allocating purchase price to assets and liabilities.
- · Revenue segments include Advisory Consulting, Managed Security Service Practice, and Software as a Service.
02-07-2026
Gentherm Inc filed an S-4 registration statement on July 2, 2026, in connection with its proposed merger with Modine's Performance Technologies business via a Reverse Morris Trust structure. The transaction involves the separation of Modine's Performance Technologies business into a newly formed SpinCo (Platinum SpinCo Inc.), followed by a merger where SpinCo becomes a wholly owned subsidiary of Gentherm. Key financial terms include a $210.0 million SpinCo Cash Distribution to Modine, a $45.0 million termination fee payable by Gentherm under certain conditions, and a Target Net Working Capital of $227.2 million (adjustable up to $232.6 million based on revenue performance).
- · The S-4 was filed on July 2, 2026, with the SEC registration number 333-.
- · The Separation Agreement was dated January 29, 2026.
- · The Credit Agreement for Permanent SpinCo Financing was dated June 29, 2026.
- · SpinCo common stock has a par value of $0.001 per share.
- · The Target Net Working Capital formula includes a base of $227,238,000 plus 20.2% of revenue growth above the $1,123,542,585 base, capped at $232,589,000.
- · The transaction is structured as a Reverse Morris Trust (RMT).
- · A special meeting of Gentherm shareholders will be held to vote on the proposals.
Get daily alerts with 12 investment signals, 10 risk alerts, 9 opportunities and full AI analysis of all 13 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US IPO Pipeline SEC S-1 Filings
🇺🇸 More from United States
View all →June 25, 2026
US Pre-Market SEC Filings Roundup — June 25, 2026
US Pre-Market SEC Filings Roundup
June 25, 2026
US Merger & Acquisition SEC Filings — June 25, 2026
US Merger & Acquisition SEC Filings
June 25, 2026
USA Insider Trading Pulse — June 25, 2026
USA Insider Trading Pulse
June 25, 2026
US Corporate Board Director Changes SEC Filings — June 25, 2026
US Corporate Board Director Changes SEC Filings